Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer.
Two independent and consecutive randomized clinical trials, conducted by the American Gynecological Oncology Group and by an European-Canadian Intergroup, have shown superiority, in clinical response rate, progression-free survival, and overall survival, of a cisplatin-paclitaxel regimen over cisplatin-cyclophosphamide given as first-line chemotherapy for women with advanced epithelial ovarian cancer. The results of these studies, published with a median follow-up of about 3 years, have been updated with a 6.5-year follow-up: In each case, an 11% absolute gain in survival favoring the paclitaxel arm is shown; this advantage remains both statistically and clinically significant and supports a role for paclitaxel in frontline chemotherapy for advanced ovarian cancer.
Piccart
M J
MJ
EORTC Gynecological Cancer Cooperative Group, Brussels, Belgium. martine.piccart@bordet.be
Bertelsen
K
K
Stuart
G
G
Cassidy
J
J
Mangioni
C
C
Simonsen
E
E
James
K
K
Kaye
S
S
Vergote
I
I
Blom
R
R
Grimshaw
R
R
Atkinson
R
R
Swenerton
K
K
Trope
C
C
Nardi
M
M
Kaern
J
J
Tumolo
S
S
Timmers
P
P
Roy
J-A
JA
Lhoas
F
F
Lidvall
B
B
Bacon
M
M
Birt
A
A
Andersen
J
J
Zee
B
B
Paul
J
J
Pecorelli
S
S
Baron
B
B
McGuire
W
W
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002170:Canada; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D005060:Europe; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008137:Longitudinal Studies; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis
D003520:Cyclophosphamide; D017239:Paclitaxel; D002945:Cisplatin